Sign in
AEZS Stock Price, Chart, Stats & News
Aeterna Zentaris Inc.
Save
17.51M
Market cap
–
Current P/E
–
Forward P/E
AEZS chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 91.31% |
Operating margin | -400.36% |
Pretax margin | -367.99% |
Net margin | -77.51% |
Effective tax rate | 5.34% |
ROA | -9.64% |
ROE | -12.51% |
D/E | 0.16x |
Interest coverage ratio | -143.12x |
AEZS valuation
P/E | – |
P/S | 3.82x |
P/B | 0.27x |
P/CF | -0.32x |
P/FCF | -1.00x |
P/OCF | -0.32x |
PEG | -0.02x |
EV multiple | -16.61x |
About
Aeterna Zentaris Inc. operates as a specialized biopharmaceutical company, dedicated to the creation and market introduction of both therapeutic drugs and diagnostic tests. Its flagship product, macimorelin, is an orally administered peptidomimetic ghrelin receptor (GHSR-1a) agonist. This compound functions by binding to the GHSR-1a, thereby stimulating the secretion of growth hormone.
Similar securities
Based on sector and market capitalization
Report issue